A new research has found that mutation on the surface of human red blood cells provides protection against common type of malaria.
According to researchers at the Case Western Reserve University School of Medicine, the minute change, at a single position of red blood cell surface protein called the Duffy blood-group antigen, has been known for years. But this difference makes it harder for Plasmodium vivax to lock onto the cell and gain entry.
Advertisement"The finding has practical implications as medical researchers continue attempts to develop a vaccine for vivax malaria," Christopher King, lead author of the study, said.
King's lab had been studying the parasite's protein, as a target for a vaccine. He teamed with his colleague Peter A. Zimmerman, whose lab was studying the mutation in the DNA sequence of Duffy blood group gene.
While investigating the binding process, they found that Duffy binding protein interaction with red blood cells varied between samples.
They performed the genetic tests for the single-point mutation. Antigens with the mutation are called Duffy 'A' and those without, Duffy 'B', and found that the parasite bound to red blood cells expressing Duffy 'B' about twice as often as the parasite bound to cells expressing Duffy 'A'.
The researchers wanted to see if the finding translated to real life.
They collaborated with Marcelo U. Ferreira, an investigator at the Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, to analyse data from 400 individuals tracked for malaria infections for more than a year in northwest Brazil.
In northwestern Brazil, where a mixture of Duffy 'A' and 'B' variants are inherited, the researchers found that people expressing the Duffy 'B' variant experience P. vivax malaria more often than those who expressed the Duffy 'A' variant.
"Therefore, stronger binding to Duffy 'B' leads to greater success at red cell invasion and more vivax malaria, Zimmerman said. "Seen from the other side of this relationship, weaker binding to Duffy 'A' appears to reduce red cell invasion and is therefore protective against vivax malaria," King said.
The analysis showed that those with the Duffy 'A'/Duffy 'A' genotype had a 29 percent reduced risk of vivax malaria. Those who had the Duffy 'A'/Duffy 'B-negative' genotype, had an 80 percent reduced risk. Reduced risk was not associated with an increase in antibodies in either case.
Those with Duffy 'B'/Duffy 'B' or Duffy 'B'/Duffy 'B-negative' genotypes had an increased risk of 220 to 270 percent for vivax malaria.
A vaccine's effectiveness therefore may depend on whether a recipient carries one or two copies of the Duffy 'A' or 'B' mutation in his DNA Dr. King said.
"The Duffy 'B' variant is ancestral to Duffy 'A'. We know this because all non-human primates carry the Duffy 'B' variant," Zimmerman said. "So a case can be made for the Duffy 'A' variant arising as protection from vivax malaria."
The study has been published online in Early Edition of the Proceedings of the National Academy of Sciences.